Bone disease in moderate renal failure: Cause, nature, and prevention

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 167-176

  Bushinsky, David A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Acidosis; Aluminum; Calcium; Dialysis; Parathyroid hormone; Vitamin D

Indexed keywords

PHOSPHORUS; VITAMIN D;

ACIDOSIS; BONE DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; HUMAN; KIDNEY FAILURE; LABORATORY DIAGNOSIS; OSTEITIS; OSTEOMALACIA; PATHOGENESIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW;

ALUMINUM; COMBINED MODALITY THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; OSTEOMALACIA; PHOSPHATES; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 0031040375     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.167     Document Type: Review

References (46)

1. Bushinsky, DA. 1996. Renal bone disease. In Textbook of Nephrology, ed. R Jamison, B Wilkinson. London: Chapman & Hall. In press
2. Goodman WG, Coburn JW, Ramirez JA, et al. 1993. Renal osteodystrophy in adults and children. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed. MJ Favus, 2:304-23. New York: Raven
3. Llach F, Bover J. 1996. Renal osteodystrophy. In The Kidney, ed. B. Brenner, 2:2187-273. Philadelphia: Saunders. 5th ed.
4. Malluche H, Faugere M-C. 1990. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 38:193-211
5. Sherrard DJ, Baylink D, Wergedal J. 1972. Bone disease in uremia. ASAIO Trans. 28: 412-15
6. Sherrard DJ, Hercz G, Pei J, et al. 1993. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int. 43:436-42
7. Pitts TO, Piraino BH, Mitro R, et al. 1988. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate and severe renal failure. J. Clin. Endocrinol. Metab. 67:876-81
8. Delmez JA, Slatopolsky E. 1992. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am. J. Kidney Dis. 19:303-17
9. Kilav R, Silver J, Naveh-Many T. 1995. Parathyroid hormone gene expression in hypophosphatemic rats. J. Clin. Invest. 96: 327-33
10. Slatopolsky E, Caglar S, Pennell JP, et al. 1971. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J. Clin. Invest. 50:492-99
11. 3. Physiol. Rev. 64:478-504
12. 3 is correlated to receptor occupancy. J. Biol. Chem. 261:16943-47
13. Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL. 1970. The role of phosphate in the secretion of parathyroid hormone in man. J. Clin. Invest. 49:2146-49
14. Russell J, Lettieri D, Sherwood LM. 1983. Direct regulation by calcium of cytoplasmic messenger RNA coding for preproparathyroid hormone in isolated bovine parathyroid cells. J. Clin. Invest. 72:1851-55
15. 3 in chick parathyroid glands. Proc. Natl. Acad. Sci. USA 72:4871-75
16. Silver J, Russell J, Sherwood LM. 1985. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 82:4270-73
17. 3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 117:2114-19
18. 3 parathyroid glands of patients with renal failure. N. Engl. J. Med. 316:1573-77
19. Andress DL, Norris KC, Coburn JW, et al. 1989. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N. Engl. J. Med. 321: 274-79
20. Brown AJ, Ritter CR, Finch JL, et al. 1989. The noncalcemic analogue of vitamin D, 22-oxocalcitriol, suppresses parathyroid hormone synthesis and secretion. J. Clin. Invest. 84:728-32
21. MacDonald PN, Ritter C, Brown AJ, Slatopolsky E. 1994. Retinoic acid suppresses parathyroid hormone (PTH) secretion and preproPTH mRNA levels in bovine parathyroid cell culture. J. Clin. Invest. 93: 725-30
22. Martin KJ, Hruska KA, Freitag JJ, et al. 1979. The peripheral metabolism of parathyroid hormone. N. Engl. J. Med. 301: 1092-98
23. Goltzman D, Henderson B, Loveridge N. 1980. Cytochemical bioassay of parathyroid hormone: characteristics of the assay and analysis of circulating hormonal forms. J. Clin. Invest. 65:1309-17
24. Bushinsky DA. 1995. Metabolic Acidosis. In The Principles and Practice of Nephrology, ed. R Jacobson, GE Striker, S Klahr, pp. 924-32. St. Louis: Mosby. 2nd ed.
25. Bushinsky DA. 1995. The contribution of acidosis to renal osteodystrophy. Kidney Int. 47:1816-32
26. Bushinsky DA, Nilsson EL. 1995. Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Am. J. Physiol. 269:C1364-70
27. Alfrey AC, LeGendre GR, Kaehny WD. 1976. The dialysis encephalopathy syndrome: possible aluminum intoxication. N. Engl. J. Med. 294:184-88
28. Platts MM, Goode GC, Hislop JS. 1977. Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br. Med. J. 2:657-60
29. Ott SM, Maloney NA, Coburn JW, et al. 1982. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N. Engl. J. Med. 307:709-13
30. Hodsman AB, Sherrard DJ, Alfrey AC, et al. 1982. Bone aluminum and histomorphometric features of renal osteodystrophy. J. Clin. Endocrinol. Metab. 54:539-46
31. Pierides AM, Edwards WG Jr, Cullu US Jr, et al. 1980. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int. 18:115-24
32. Maloney NA, Ott SM, Alfrey AC, et al. 1982. Histological quantitation of aluminum in iliac bone from patients with renal failure. J. Lab. Clin. Med. 99:206-16
33. Goodman WG, Henry DA, Horst R, et al. 1984. Parenteral aluminum administration in the dog. II. Induction of osteomalacia and effect of vitamin D metabolism. Kidney Int. 25:370-75
34. Goodman WG, Gilligan J, Horst R. 1984. Short-term aluminum administration in the rat. Effects on bone formation and relationship to renal osteomalacia. J. Clin. Invest. 73:171-81
35. Sprague SM, Krieger NS, Bushinsky DA. 1993. Aluminum inhibits bone nodule formation and calcification in vitro. Am. J. Physiol. 264:F882-90
36. Sprague SM, Bushinsky DA. 1990. Mechanism of aluminum-induced calcium efflux from cultured neonatal mouse calvariae. Am. J. Physiol. 258:F583-88
37. Hercz G, Pei Y, Greenwood A, et al. 1993. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int. 44:860-66
38. Salusky IB, Coburn JW, Brill J, et al. 1988. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 33:975-82
39. Christiansen CL, Rodbro P, Christensen MS, et al. 1978. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2:700-3
40. 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 35:661-69
41. Bushinsky DA. 1995. Stimulated osteoclastic and suppressed osteoblastic activity in metabolic but not respiratory acidosis. Am. J. Physiol. 268:C80-88
42. Bushinsky DA, Wolbach W, Sessler NE, et al. 1993. Physicochemical effects of acidosis on bone calcium flux and surface ion composition. J. Bone Min. Res. 8:93-102
43. Clarkson EM, McDonald SJ, DeWardener HE. 1966. The effect of high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. 30:425-38
44. Makoff DL, Gordon A, Franklin SS, et al. 1969. Chronic calcium carbonate therapy in uremia. Arch. Intern. Med. 123:15-21
45. Harris DCH, Yuill E, Chesher DW. 1995. Correcting acidosis in hemodialysis: effect on phosphate clearance and calcification risk. J. Am. Soc. Nephrol. 6:1607-12
46. Bushinsky DA, Krieger NS. 1992. Role of the skeleton in calcium homeostasis. In The Kidney: Physiology and Pathophysiology, ed. DW Seldin, G Giebisch, 2:2395-430. New York: Raven. 2nd ed.